JCI Editorial Board
First-tier potential conflicts of interest

Aegerion Pharma (D Rader)

Astra Zeneca (D Rader)

Cytos Biotechnology (Y Choi)

Forbes Medi-tech (D Rader)

Fresenius Medical Care (S Goldfarb)

General Electric (Goldfarb, Stanley)

GlaxoSmithKline (D Rader, L Turka, K Honey)

Life Sciences (J Stanley)

Lilly (D Rader)

Merck (R Collman, D Rader, J Weiser)

Metabolex, Inc. (M Birnbaum)

Motif Biosciences, Inc. (M Birnbaum)

Myriad Genetics (L Turka)

Novartis (L Turka)

Polymedix inc (S Goldfarb)

Procter & Gamble (J Stanley)

Takeda (D Rader)

Unilever (J Stanley)

Wyeth (D Rader)